Baqsimi

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Descarcare Prospect (PIL)
05-07-2021

Ingredient activ:

Glucagon

Disponibil de la:

Eli Lilly Nederland B.V.

Codul ATC:

H04AA01

INN (nume internaţional):

glucagon

Grupul Terapeutică:

Pancreatic hormones, Glycogenolytic hormones

Zonă Terapeutică:

Diabetes Mellitus

Indicații terapeutice:

Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.

Rezumat produs:

Revision: 1

Statutul autorizaţiei:

Authorised

Data de autorizare:

2019-12-16

Prospect

                                23
B. PACKAGE LEAFLET
24
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
BAQSIMI 3 MG NASAL POWDER IN SINGLE-DOSE CONTAINER
glucagon
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Baqsimi is and what it is used for
2.
What you need to know before you are given Baqsimi
3.
How Baqsimi is given
4.
Possible side effects
5.
How to store Baqsimi
6.
Contents of the pack and other information
1.
WHAT BAQSIMI IS AND WHAT IT IS USED FOR
Baqsimi contains the active substance glucagon, which belongs to a
group of medicines called
glycogenolytic hormones. It is used to treat severe hypoglycaemia
(very low blood sugar) in people
with diabetes. It is for use in adults, adolescents, and children aged
4 years or older.
Glucagon is a natural hormone produced by the pancreas. It works in
the opposite way to insulin and
raises blood sugar. It does this by converting stored sugar in the
liver called glycogen to glucose (a
form of sugar that the body uses for energy). The glucose then enters
the bloodstream and raises the
blood sugar level, so reducing the effects of hypoglycaemia.
You should always carry Baqsimi with you and tell your friends and
family that you are carrying it.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN BAQSIMI
_ _
IMPORTANT INFORMATION
If you are at risk of severe hypoglycaemia you should always have
Baqsimi readily available:
-
show your family members, friends, or people you work with where you
keep this medicine and
explain when and how to use it. Delay in treatment may be harmful
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Baqsimi 3 mg nasal powder in single-dose container
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each single-dose container delivers nasal powder with 3 mg of
glucagon.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Nasal powder in single-dose container (nasal powder).
White to practically white powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Baqsimi is indicated for the treatment of severe hypoglycaemia in
adults, adolescents, and children
aged 4 years and over with diabetes mellitus.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults, adolescents and children aged 4 years and over _
The recommended dose is 3 mg glucagon administered into one nostril.
_Elderly _
(≥ 65 years)
_ _
No dose adjustment is required based on age.
Efficacy and safety data are very limited in patients aged 65 years
and absent in patients aged 75 and
above.
_ _
_Renal and hepatic impairment _
No dose adjustment is required based on renal and hepatic function.
_ _
_Paediatric population 0 - < 4 years _
The safety and efficacy of Baqsimi in infants and children aged 0 to <
4 years have not yet been
established. No data are available.
Method of administration
Nasal use only. Glucagon nasal powder is given in a single nostril.
Glucagon is passively absorbed
through the nasal mucosa. It is not necessary to inhale or breathe
deeply after dosing.
INSTRUCTIONS FOR ADMINISTERING GLUCAGON NASAL POWDER
1.
Remove the shrink wrap by pulling on the red stripe.
2.
Remove the single-dose container from the tube. Do not press the
plunger until ready to give the
dose.
3.
Hold the single-dose container between fingers and thumb. Do not test
before use as it contains
3
only one dose of glucagon and cannot be reused.
4.
Insert the tip of the single-dose container gently in one of the
nostrils until finger(s) touch the
outside of the nose.
5.
Push the plunger all the way in. The dose is complete when the green
line is no longer show
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului bulgară 05-07-2021
Raport public de evaluare Raport public de evaluare bulgară 06-02-2020
Prospect Prospect spaniolă 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului spaniolă 05-07-2021
Raport public de evaluare Raport public de evaluare spaniolă 06-02-2020
Prospect Prospect cehă 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului cehă 05-07-2021
Raport public de evaluare Raport public de evaluare cehă 06-02-2020
Prospect Prospect daneză 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului daneză 05-07-2021
Raport public de evaluare Raport public de evaluare daneză 06-02-2020
Prospect Prospect germană 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului germană 05-07-2021
Raport public de evaluare Raport public de evaluare germană 06-02-2020
Prospect Prospect estoniană 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului estoniană 05-07-2021
Raport public de evaluare Raport public de evaluare estoniană 06-02-2020
Prospect Prospect greacă 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului greacă 05-07-2021
Raport public de evaluare Raport public de evaluare greacă 06-02-2020
Prospect Prospect franceză 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului franceză 05-07-2021
Raport public de evaluare Raport public de evaluare franceză 06-02-2020
Prospect Prospect italiană 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului italiană 05-07-2021
Raport public de evaluare Raport public de evaluare italiană 06-02-2020
Prospect Prospect letonă 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului letonă 05-07-2021
Raport public de evaluare Raport public de evaluare letonă 06-02-2020
Prospect Prospect lituaniană 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului lituaniană 05-07-2021
Raport public de evaluare Raport public de evaluare lituaniană 06-02-2020
Prospect Prospect maghiară 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului maghiară 05-07-2021
Raport public de evaluare Raport public de evaluare maghiară 06-02-2020
Prospect Prospect malteză 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului malteză 05-07-2021
Raport public de evaluare Raport public de evaluare malteză 06-02-2020
Prospect Prospect olandeză 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului olandeză 05-07-2021
Raport public de evaluare Raport public de evaluare olandeză 06-02-2020
Prospect Prospect poloneză 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului poloneză 05-07-2021
Raport public de evaluare Raport public de evaluare poloneză 06-02-2020
Prospect Prospect portugheză 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului portugheză 05-07-2021
Raport public de evaluare Raport public de evaluare portugheză 06-02-2020
Prospect Prospect română 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului română 05-07-2021
Raport public de evaluare Raport public de evaluare română 06-02-2020
Prospect Prospect slovacă 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului slovacă 05-07-2021
Raport public de evaluare Raport public de evaluare slovacă 06-02-2020
Prospect Prospect slovenă 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului slovenă 05-07-2021
Raport public de evaluare Raport public de evaluare slovenă 06-02-2020
Prospect Prospect finlandeză 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului finlandeză 05-07-2021
Raport public de evaluare Raport public de evaluare finlandeză 06-02-2020
Prospect Prospect suedeză 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului suedeză 05-07-2021
Raport public de evaluare Raport public de evaluare suedeză 06-02-2020
Prospect Prospect norvegiană 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului norvegiană 05-07-2021
Prospect Prospect islandeză 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului islandeză 05-07-2021
Prospect Prospect croată 05-07-2021
Caracteristicilor produsului Caracteristicilor produsului croată 05-07-2021
Raport public de evaluare Raport public de evaluare croată 06-02-2020

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor